Rhofade (Oxymetazoline HCl) Patent Expiration, LOE Window & CMS Spending

Rhofade (Oxymetazoline HCl) by Mayne: FDA Orange Book LOE 2035-06-11, 1 AB generics, $3.6M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMayne
FDA Application & PathwayN208552 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-06-11
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$3.6M
2024 Medicare Part D Spend$928K
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 24.2% 2-yr change)